Trial Profile
A Phase I Safety and Tolerability Study of T-1101 (Tosylate) as a Oral Powder for Constitution (OPC) in Patients With Advanced Refractory Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 20 Nov 2022
Price :
$35
*
At a glance
- Drugs T 1101 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Taivex Therapeutics
- 14 Apr 2021 Status changed from active, no longer recruiting to discontinued before the primary endpoint (determination of MTD) was reached because the OPC form is to be replaced with the newly developed capsule form in all subsequent clinical trials.
- 28 Jan 2021 Planned End Date changed from 31 Dec 2020 to 31 May 2021.
- 28 Jan 2021 Planned primary completion date changed from 31 Dec 2020 to 30 Apr 2021.